ArticleAmerican journal of translational research2025
Therapeutic efficacy of different sulperazon dosing regimens in carbapenem-resistant Klebsiella pneumoniae: a retrospective analysis of 209 cases.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical Epidemiological Analysis of the Genotypic Spectrum and Mortality Risk in Carbapenem-ResistantThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesCarbapenem-resistant
methodsA retrospective analysis was conducted on 209 adult patients with CRKP infections treated with sulperazon for at least 48 hours at Bengbu First People's Hospital between January 2020 and December 2022. Patients were grouped into a standard-dose group (≤3 g/day, n=112) and a high-dose group (>3 g/day, n=97). Clinical cure, microbiological eradication, treatment failure, 28-day mortality, and incidence of adverse events were compared between groups.
resultsThe cohort was predominantly elderly (mean age 67.3 ± 15.2 years) and male (65.1%). The most frequent carbapenemase genes were
conclusionHigh-dose sulperazon demonstrated superior clinical efficacy and equivalent safety to standard dosing in the treatment of CRKP infections, supporting dose optimization to improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.